DK0469082T3 - Liposomal målretning mod iskæmiske væv - Google Patents

Liposomal målretning mod iskæmiske væv

Info

Publication number
DK0469082T3
DK0469082T3 DK90907986.5T DK90907986T DK0469082T3 DK 0469082 T3 DK0469082 T3 DK 0469082T3 DK 90907986 T DK90907986 T DK 90907986T DK 0469082 T3 DK0469082 T3 DK 0469082T3
Authority
DK
Denmark
Prior art keywords
ischemic tissues
liposomal targeting
liposomes
liposomal
targeting
Prior art date
Application number
DK90907986.5T
Other languages
English (en)
Inventor
John D Baldeschwieler
Original Assignee
Nexstar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexstar Pharmaceuticals Inc filed Critical Nexstar Pharmaceuticals Inc
Application granted granted Critical
Publication of DK0469082T3 publication Critical patent/DK0469082T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/806—Virus-based particle with exterior chemical attachment
    • Y10S977/808—Exterior attachment for targeting, e.g. drug targeting
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK90907986.5T 1989-04-18 1990-04-13 Liposomal målretning mod iskæmiske væv DK0469082T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33968289A 1989-04-18 1989-04-18
US41171689A 1989-09-25 1989-09-25

Publications (1)

Publication Number Publication Date
DK0469082T3 true DK0469082T3 (da) 1995-08-28

Family

ID=26991750

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90907986.5T DK0469082T3 (da) 1989-04-18 1990-04-13 Liposomal målretning mod iskæmiske væv

Country Status (9)

Country Link
US (1) US5527538A (da)
EP (1) EP0469082B1 (da)
JP (1) JP3010500B2 (da)
AT (1) ATE120640T1 (da)
AU (1) AU639925B2 (da)
DE (1) DE69018460T2 (da)
DK (1) DK0469082T3 (da)
ES (1) ES2073574T3 (da)
WO (1) WO1990012595A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6312719B1 (en) * 1994-03-04 2001-11-06 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
DE4430592A1 (de) * 1994-08-20 1996-02-22 Max Delbrueck Centrum Liposomale Zubereitung, ihre Herstellung und ihre Verwendung
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
JP4058775B2 (ja) * 1996-06-26 2008-03-12 ザ ウィタカー コーポレーション 電気コネクタ
US7309692B1 (en) * 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6689485B2 (en) * 1997-01-17 2004-02-10 The Penn State Research Foundation Powerful reductant for decontamination of groundwater and surface streams
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
PL369545A1 (en) * 2001-09-28 2005-05-02 Esperion Therapeutics, Inc. Methods and apparatus for extrusion of vesicles at high pressure
US20040043950A1 (en) * 2002-01-03 2004-03-04 Board Of Regents, The University Of Texas System WT1 antisense oligos for the inhibition of breast cancer
US20050058698A1 (en) * 2002-01-21 2005-03-17 Nolan Yvonne Mairead Pharmaceutically acceptable phosphate-glycerol carrying bodies and uses relating to Parkinson's Disease
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
WO2004074314A2 (en) * 2003-02-14 2004-09-02 University Of South Florida Chistosan-microparticles for ifn gene delivery
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
JP5333970B2 (ja) * 2007-03-20 2013-11-06 国立大学法人大阪大学 心筋梗塞の予防および／または治療薬
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873088A (en) * 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4728575A (en) * 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
DE3515335C2 (de) * 1985-04-27 1995-01-26 Bayer Ag Arzneizubereitung enthaltend Dihydropyridine und Verfahren zu ihrer Herstellung
WO1988007851A1 (en) * 1987-04-06 1988-10-20 Innovative Therapeutics Corporation Liposome entrapped n-methyl-d-aspartate receptor blockers
JPH0262829A (ja) * 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤

Also Published As

Publication number Publication date
DE69018460T2 (de) 1995-11-09
JP3010500B2 (ja) 2000-02-21
EP0469082A1 (en) 1992-02-05
WO1990012595A1 (en) 1990-11-01
EP0469082B1 (en) 1995-04-05
US5527538A (en) 1996-06-18
ATE120640T1 (de) 1995-04-15
EP0469082A4 (en) 1992-06-17
AU639925B2 (en) 1993-08-12
AU5543490A (en) 1990-11-16
JPH04507090A (ja) 1992-12-10
ES2073574T3 (es) 1995-08-16
DE69018460D1 (de) 1995-05-11

Similar Documents

Publication Publication Date Title
DK0469082T3 (da) Liposomal målretning mod iskæmiske væv
EP0225130A3 (en) Liposome composition
DK0774959T3 (da) Liposomalt indgivelsessystem for biologisk aktive midler
ES2013129A6 (es) Procedimiento de obtencion de una composicion farmaceutica a base de n-metil-n- (1-fenil -2- propil) -2- propinilamina.
DK0859596T3 (da) Vækstfaktorholdige gelformuleringer
GR1000074B (el) Λιποειδη σφαιριδια (κυστιδια) για ενδοπεριτονειακη χορηγηση θεραπευτικων παραγοντων.
ATE245662T1 (de) Avidin-biotin immunokonjugate
DE69627690D1 (de) Liposomale formulierungen von mitoxantron
ATE76296T1 (de) Pharmazeutische zusammensetzung zur behandlung von akuter myocardischer ischaemie.
FR2784294B1 (fr) Composition cosmetique et/ou dermatologique renfermant au moins un extrait de murier, au moins un extrait de scutellaire et au moins un derive d'acide salicylique
CA2203033A1 (en) Compounds and compositions for delivering active agents
CA2033725A1 (en) Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
ES2095141T3 (es) Composicion hidratante para el tratamiento simultaneo de las capas superficiales y profundas de la piel, su utilizacion.
ATE220911T1 (de) Transdermal absorbierbare zubereitung
CA2032059A1 (en) Wound treatment employing biologically active peptides
DE69332276D1 (de) Liposomenzusammensetzung
ATE322255T1 (de) Polyamid-oligomere
PT941063E (pt) Composicoes transdermicas contendo levosimendano
TR199903192T2 (xx) Eritropoetin, de�i�tirilmi� hemoglobin i�eren farmasotik kombine m�stahzarlar.
CA2051439A1 (en) Liposomal targeting of ischemic tissue
FR2549835B1 (fr) Acides peneme-carboxyliques, leur preparation et leur utilisation therapeutique, notamment en tant qu'agents antibacteriens
DE69804674D1 (de) Liposomen mit mehrfach verzweigten peptidkonstruktionen zur verwendung gegen hiv
FI964448A (fi) Uusi biologisesti aktiivinen peptidi ja sen valmistus
IT8820984A0 (it) Impiego di un agonista colinergico e di ormone che stimola il rilascio dell'ormone della crescita per la preparazionedi composizioni farmaceutiche aventi utilita' nella diagnosi differenziale della carenza somatotropa.